Plasma Mutational Burden in PIK3CA and TP53 Independently Predicts Early Progression in Patients with HR+/HER2- Metastatic Breast Cancer (MBC) Enrolled in the GEICAM/2014-12 FLIPPER Trial.

Federico Gustavo,Rojo Todo, Lara Meier,Maria Teresa Martinez,Maria Esteban Lopez,Lorena Paris,Miriam O'Connor,Luis De la Cruz Merino,Ana Santaballa,Noelia Martinez-Janez,Fernando Moreno Anton,Isaura Fernandez,Maccon Keane,Andres Garcia-Palomo,Anna Starus, Marta Portela,Jesus Herranz,Rosalia Caballero,Frederick Jones,Joan Albanell

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用 0|浏览20

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要